Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin

A report from the childrens cancer study group

S. A. Feig, M. D. Krailo, R. E. Harris, E. Baum, J. S. Holcenberg, H. Kaizer, L. Steinherz, T. W. Pendergrass, E. F. Saunders, Phyllis Irene Warkentin, W. A. Bleyer, G. D. Hammond

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75%) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59%) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses.

Original languageEnglish (US)
Pages (from-to)124-129
Number of pages6
JournalMedical and Pediatric Oncology
Volume20
Issue number2
DOIs
StatePublished - Jan 1 1992

Fingerprint

Idarubicin
Daunorubicin
Maximum Tolerated Dose
Combination Drug Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Recurrence
Neoplasms
Vincristine
Prednisone
Sepsis
Hospitalization

Keywords

  • idarubicin
  • lymphoblastic leukemia
  • toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin : A report from the childrens cancer study group. / Feig, S. A.; Krailo, M. D.; Harris, R. E.; Baum, E.; Holcenberg, J. S.; Kaizer, H.; Steinherz, L.; Pendergrass, T. W.; Saunders, E. F.; Warkentin, Phyllis Irene; Bleyer, W. A.; Hammond, G. D.

In: Medical and Pediatric Oncology, Vol. 20, No. 2, 01.01.1992, p. 124-129.

Research output: Contribution to journalArticle

@article{8fe9cb77977e4fc1b7669525a3675627,
title = "Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the childrens cancer study group",
abstract = "An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75{\%}) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59{\%}) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses.",
keywords = "idarubicin, lymphoblastic leukemia, toxicity",
author = "Feig, {S. A.} and Krailo, {M. D.} and Harris, {R. E.} and E. Baum and Holcenberg, {J. S.} and H. Kaizer and L. Steinherz and Pendergrass, {T. W.} and Saunders, {E. F.} and Warkentin, {Phyllis Irene} and Bleyer, {W. A.} and Hammond, {G. D.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/mpo.2950200207",
language = "English (US)",
volume = "20",
pages = "124--129",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin

T2 - A report from the childrens cancer study group

AU - Feig, S. A.

AU - Krailo, M. D.

AU - Harris, R. E.

AU - Baum, E.

AU - Holcenberg, J. S.

AU - Kaizer, H.

AU - Steinherz, L.

AU - Pendergrass, T. W.

AU - Saunders, E. F.

AU - Warkentin, Phyllis Irene

AU - Bleyer, W. A.

AU - Hammond, G. D.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75%) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59%) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses.

AB - An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75%) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59%) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses.

KW - idarubicin

KW - lymphoblastic leukemia

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=0026623186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026623186&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950200207

DO - 10.1002/mpo.2950200207

M3 - Article

VL - 20

SP - 124

EP - 129

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -